Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HJZXJ
ADC Name
Trastuzumab-Val-Cit linker-MMAE 2
Synonyms
Trastuzumab-Val-Cit linker-MMAE 2
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
2
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Val-Cit linker 2e
  Linker Info 
Conjugate Type
Site-specific conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.18
nM
BT-474 cells
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.18 nM Positive HER2 expression (HER2+++/++)
Method Description
Cells were seeded at 2000 cells per well in black 96-well proliferation plates and dosed with a titration of conjugates for 3 to 5 days, until control untreated cells reached 80 to 90% confluence.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
References
Ref 1 Peroxide-cleavable linkers for antibody-drug conjugates. Chem Commun (Camb). 2023 Feb 9;59(13):1841-1844. doi: 10.1039/d2cc06677g.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.